Danish pharma group plans 1.4mn sq ft manufacturing plant in North Carolina to help meet surging demand
Oral formulation offers prospect of cheaper and more convenient access to drug, research suggests
Vutrisiran injection cut risk of death and adverse cardiovascular events by at least 28%, company says
As incidence rises, breakthroughs in oncology show the value of research funding
Both OZEM and THNR offer very concentrated bets on a fast-moving market
US decision hands biotech group its first regulatory blessing since its blockbuster Covid-19 jab
US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness
US drugmaker races to scale up ingredient production to meet demand for Mounjaro and Zepbound jabs
As Covid revenues slump, technology developed to fight the pandemic is having some success combating this disease
Weekly injection delivered 18.8% weight loss over 24 weeks
Study opens up potential to tackle a condition with few available treatment options
Trial participants also had cardiovascular benefits regardless of weight
Food and Drug Administration poised to call for outside assessment of Lykos PTSD therapy in test for psychedelics sector
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Breakthrough medicine will now be subject to further review by committee of independent experts
Drugmaker releases promising trial results for a pill and expects to enter China this year
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
New Pasteur Institute head highlights risks posed by shortages of money, staff and political goodwill
UK Edition